Abstract Number: 1434 • 2019 ACR/ARP Annual Meeting
Improvement in Matrix metalloproteinase-3 Levels at 12 Weeks Independently Predicts Achievement of Low Disease Activity at 52 Weeks in Bio-switch Patients with Rheumatoid Arthritis Treated with Abatacept
Background/Purpose: Japanese post-marketing surveillance (PMS) data demonstrated that effectiveness of abatacept in rheumatoid arthritis (RA) patients with previous biologics treatment (bio-switch) was significantly lower than…Abstract Number: 1435 • 2019 ACR/ARP Annual Meeting
Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis
Background/Purpose: Wnt signaling is an important regulator of bone remodeling and it is involved in the pathogenesis of focal and systemic bone loss in Rheumatoid…Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting
Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting
Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…Abstract Number: 1438 • 2019 ACR/ARP Annual Meeting
Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…Abstract Number: 1439 • 2019 ACR/ARP Annual Meeting
Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs
Background/Purpose: In RA, disease activity correlates with physical function1 and there is a link between joint damage and functional disability2. In many countries, RA patients…Abstract Number: 1440 • 2019 ACR/ARP Annual Meeting
Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis
Background/Purpose: Therapeutic drug monitoring (TDM) would be important if there was evidence to support the utility of measured drug concentrations in making changes to dose…Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting
Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting
Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…Abstract Number: 1443 • 2019 ACR/ARP Annual Meeting
Real World Switching Patterns of Etanercept Original and Biosilmilar in Germany
Background/Purpose: We have previously evaluated switching dynamics between etanercept biologic original (EtnBO) and etanercept biosimilars (EtnBS) over approximately 18 months following the first EtnBS launch…Abstract Number: 1444 • 2019 ACR/ARP Annual Meeting
Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
Background/Purpose: Depression and anxiety are common in patients (pts) with RA1 and can lead to reduced quality of life, functional capacity, and RA treatment response.2-4…Abstract Number: 1445 • 2019 ACR/ARP Annual Meeting
Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States
Background/Purpose: Tofacitinib was the first Janus kinase (JAK) inhibitor FDA approved for the treatment of RA in November 2012, five- and one-half years later, baricitinib,…Abstract Number: 1446 • 2019 ACR/ARP Annual Meeting
Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in…Abstract Number: 1447 • 2019 ACR/ARP Annual Meeting
Comparison of Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands and Conventional Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome Assessment
Background/Purpose: Labial salivary gland (LSG) biopsy remains a key tool for the diagnosis of primary Sjögren’s syndrome (pSS). Nowadays, however, interest is growing in non‐invasive…Abstract Number: 1448 • 2019 ACR/ARP Annual Meeting
Ultrasonography of Major Salivary Glands in Primary Sjögren’s Syndrome: Identification of Distinct Evolving Patterns in the Long-Term Follow-up
Background/Purpose: to evaluate the longitudinal changes of major salivary glands ultrasonography (SGUS) in primary Sjögren’s Syndrome (pSS) and to investigate its relationship with patients’ imaging…
- « Previous Page
- 1
- …
- 852
- 853
- 854
- 855
- 856
- …
- 2425
- Next Page »